knowledge -WSS

knowledge

author：comprehensive 2025-09-29 21:23:08 - browse：316

ANDREW YATES/AFP via Getty Images

WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program.

Colm Connolly, chief judge of the U.S. District Court of Delaware, ruled against the company on all its major arguments. He wrote that AstraZeneca had not proved that Medicare’s new drug price negotiation program jeopardizes its constitutional property rights, and that the company didn’t have standing to challenge the guidance Medicare issued to implement the program.

The case is the first of a slew of cases filed by the pharmaceutical industry and its allies to be decided at the district court level. The Delaware ruling is a blow, as several of the other cases made similar arguments about how the program violates drugmakers’ constitutional property rights.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Letters to First Opinion on caregivers, digital health, and more

explore

WSS

Cord blood banking comes at a high cost to babies

FDA proposes changes to key medical devices approval pathway

FDA's Pazdur wants cancer trials to range beyond China alone

WATCH: Why do bright lights make us see spots?

Innovation in antibiotics is ailing. 'Brain drain' may kill it

PEPFAR is under serious threat — and so is global health

leisure time

knowledge

focus

Heart attack and stroke risk calculators need revising

New weight loss drugs vying to be the next Wegovy or Mounjaro

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

PEPFAR is under serious threat — and so is global health

Affirmative action in medical school literally saved lives

FDA proposes changes to key medical devices approval pathway

United colonoscopy coverage change 'may cost lives,' doctors say

Private equity could exacerbate cardiology's overuse problem, experts fear

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Will the IRA bring competition to the biologics market?

hotspot

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

NIH documents show early flaws of $1.6 billion long Covid program

Private equity could exacerbate cardiology's overuse problem, experts fear

The Pandemic Treaty must support building strong health systems

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

leisure time

explore

leisure time

knowledge